Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.

S. J. Kim; W. S. Kim

doi:10.1093/annonc/mdw296

Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.

Department of Internal Medicine

Research output: Contribution to journal › Letter › peer-review

Abstract

This is our reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.

Original language	English
Pages (from-to)	2133-2134
Number of pages	2
Journal	Annals of Oncology
Volume	27
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mdw296
State	Published - Nov 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/annonc/mdw296

Fingerprint

Dive into the research topics of 'Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.'. Together they form a unique fingerprint.

Cite this

Kim, S. J., & Kim, W. S. (2016). Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al. Annals of Oncology, 27(11), 2133-2134. https://doi.org/10.1093/annonc/mdw296

Kim, S. J. ; Kim, W. S. / Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients : a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al. In: Annals of Oncology. 2016 ; Vol. 27, No. 11. pp. 2133-2134.

@article{9ba2ef6a4ae94ebf81701ed7f2fb78ac,

title = "Reply to the letter to the editor {\textquoteleft}Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma{\textquoteright} by Tan et al.",

abstract = "This is our reply to the letter to the editor {\textquoteleft}Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma{\textquoteright} by Tan et al.",

author = "Kim, \{S. J.\} and Kim, \{W. S.\}",

note = "Publisher Copyright: {\textcopyright} 2016 European Society for Medical Oncology",

year = "2016",

month = nov,

doi = "10.1093/annonc/mdw296",

language = "English",

volume = "27",

pages = "2133--2134",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "11",

}

Kim, SJ & Kim, WS 2016, 'Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.', Annals of Oncology, vol. 27, no. 11, pp. 2133-2134. https://doi.org/10.1093/annonc/mdw296

Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al. / Kim, S. J.; Kim, W. S.
In: Annals of Oncology, Vol. 27, No. 11, 11.2016, p. 2133-2134.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients

T2 - a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.

AU - Kim, S. J.

AU - Kim, W. S.

PY - 2016/11

Y1 - 2016/11

N2 - This is our reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.

AB - This is our reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.

UR - https://www.scopus.com/pages/publications/85040665507

U2 - 10.1093/annonc/mdw296

DO - 10.1093/annonc/mdw296

M3 - Letter

C2 - 27502713

AN - SCOPUS:85040665507

SN - 0923-7534

VL - 27

SP - 2133

EP - 2134

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Kim SJ , Kim WS. Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al. Annals of Oncology. 2016 Nov;27(11):2133-2134. doi: 10.1093/annonc/mdw296

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this